National Pension Service Trims Position in Alnylam Pharmaceuticals, Inc. $ALNY

National Pension Service cut its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 168,149 shares of the biopharmaceutical company’s stock after selling 9,089 shares during the period. National Pension Service’s holdings in Alnylam Pharmaceuticals were worth $66,864,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Mediolanum International Funds Ltd purchased a new stake in Alnylam Pharmaceuticals in the third quarter worth $11,389,000. iA Global Asset Management Inc. grew its holdings in Alnylam Pharmaceuticals by 979.5% in the fourth quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock worth $7,070,000 after purchasing an additional 16,133 shares during the period. Perpetual Ltd purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter worth about $2,004,000. Vanguard Group Inc. grew its holdings in Alnylam Pharmaceuticals by 2.0% in the third quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock worth $6,185,846,000 after purchasing an additional 268,313 shares during the period. Finally, Envestnet Asset Management Inc. grew its holdings in Alnylam Pharmaceuticals by 24.2% in the third quarter. Envestnet Asset Management Inc. now owns 118,964 shares of the biopharmaceutical company’s stock worth $54,248,000 after purchasing an additional 23,168 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ALNY. Needham & Company LLC dropped their price target on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a research report on Thursday, February 12th. Jefferies Financial Group reissued a “hold” rating and issued a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, March 16th. Wells Fargo & Company boosted their price target on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a research report on Friday, May 1st. Citigroup initiated coverage on Alnylam Pharmaceuticals in a report on Tuesday, May 19th. They issued a “buy” rating and a $380.00 target price on the stock. Finally, Bank of America reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $463.13.

Alnylam Pharmaceuticals Trading Down 1.0%

Alnylam Pharmaceuticals stock opened at $301.98 on Friday. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. The business’s fifty day simple moving average is $309.38 and its two-hundred day simple moving average is $354.73. Alnylam Pharmaceuticals, Inc. has a 12 month low of $284.28 and a 12 month high of $495.55. The company has a market capitalization of $40.32 billion, a price-to-earnings ratio of 82.51 and a beta of 0.31.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $0.87 by $1.12. The company had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The firm’s quarterly revenue was up 96.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.44) earnings per share. As a group, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.36 earnings per share for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Tolga Tanguler sold 1,598 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $523,584.70. Following the transaction, the executive vice president directly owned 36,606 shares of the company’s stock, valued at $11,993,955.90. This represents a 4.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Yvonne Greenstreet sold 6,799 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total value of $2,227,692.35. Following the transaction, the chief executive officer directly owned 98,628 shares in the company, valued at approximately $32,315,464.20. The trade was a 6.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 21,255 shares of company stock valued at $6,930,337 over the last ninety days. Corporate insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.